Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated
worsening of disability, which is assumed to be mainly associated with transient infiltration of …

B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies.
Activation of BCR signaling promotes the survival and proliferation of malignant B cells …

Bruton's tyrosine kinase (BTK) is crucial for FcεRI-mediated mast cell activation and
essential for autoantibody production by B cells in chronic spontaneous urticaria (CSU) …

Objective Fenebrutinib (GDC‐0853) is a noncovalent, oral, and highly selective inhibitor of
Bruton's tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib …

Objective To evaluate fenebrutinib, an oral and highly selective noncovalent inhibitor of
Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arthritis (RA). Methods …

Bruton's tyrosine kinase (BTK), a member of the Tec kinase family, is critically involved in a
range of immunological pathways. The clinical application of BTK inhibitors for B‐cell …

Abstract Pirtobrutinib (LOXO-305), a reversible inhibitor of Bruton's tyrosine kinase (BTK),
was designed as an alternative strategy to treat ibrutinib-resistant disease that develops due …

The use of Bruton's tyrosine kinase (BTK) inhibitors has changed the management of
patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects …

Abstract Purpose of Review Multiple sclerosis (MS) is an inflammatory disease of the central
nervous system (CNS) with a chronic and often progressive disease course. The current …

Bruton's tyrosine kinase (BTK) regulates multiple important signaling pathways and plays a
key role in the proliferation, survival, and differentiation of B-lineage cells and myeloid cells …